Rumen Fermentation and Microbial Protein Synthesis of Bali Cattle Heifers (Bos sondaicus ) Fed Ration Containing Different Energy Protein Level

The purpose of this study was to determine the effect of energy and protein levels on rumen fermentation, microbial protein synthesis of Bali cattle heifers. The study was conducted in Petang Village, Badung Regency, Province of Bali Indonesia on 12 Bali cattle heifers with initial body weight 193,67 ± 22,55 kg/head. The treatment given is four types of ration consists of different level of metabolizable energy (ME) and crude protein (CP): ME 2051.41 kcal/kg: 12.04% CP (Treatment A); ME 2107.79 kcal/kg : 13.05% CP (Treatment B); ME 2194.06 kcal/kg : 14.04% CP (Treatment C) and ME 2294.23 kcal/kg : 15.09% CP (Treatment D). Variables measured: nutrient intake, rumen fermentation, microbial protein synthesis and growth performance of Bali cattle heifer age of 18 month. This research was a randomized block design. The results showed that increase in ME to 2294.23 kcal /kg and 15.09% CP significantly (P <0.05) increased energy intake to 17,880.57 kcal /day and protein intake 686.56 g /day. Rumen fermentation was also highest (P <0.05) in treatment D seen from total VFA, propionic acid and butyric acid respectively 170.32 mMol, 28.52 mMol and 13.70 mMol. While acetic acid, methane and NGR significantly decreased (P <0.05) respectively 57.77 mMol, 18.38 mMol and 3.07. This resulted in the highest rumen microbial protein synthesis in treatment D which was 562.06 g / day so that it was able to produce the highest ADG too, which was 0.42 kg /day. This study concluded that giving rations containing ME 2294.23 kcal /kg and 15.09% CP increased rumen fermentation and microbial protein synthesis, resulting in the highest growth compared to lower levels

Increasing Energy Ration of Bali Cattle to Improve Digestible Nutrient, Milk Yield and Milk Quality

To determine the effect of energy levels on digestible nutrient, milk production and milk quality of 7 months pregnant Bali cattle, was the purpose of this study. The study was conducted in Bali, Province of Indonesia on 12 pregnant breeding phase of pre-calving (2 months before the birth) with the parent body weight 329-340 kg/head. The treatment given is four types of Metabolizable Energy (ME) levels: 2000, 2100, 2200 and 2300/kg respectively as treatment A, B, C, and D. All ration contain 10% of crude protein. Variables measured: energy intake, digestible nutrient, milk yield, and milk quality. This research is a randomized block design. The results showed that increase energy ration until 2300 kcal ME/kg would significantly (P&lt;0.05) increase energy intake and highest at cattle consumed ratio D is 22239.55 kcal/day. However, digestible nutrient was not affected. Milk production increased with increasing energy rations and highest (P&lt;0.05) at cattle received treatment D is 2179.83 ml/day compared to treatment A 936.67 ml/day. Milk fat and milk lactose also highest (P&lt;0.05) in treatment D are 8.56% and 4.76% respectively. Based on these results, it can be concluded that increase energy ration will increase energy intake, milk yield, and milk fat and milk lactose of Bali cattle

Proteoglycan-4 Regulates Fibroblast to Myofibroblast Transition and Expression of Fibrotic Genes in the Synovium

Background: Synovial tissue fibrosis is common in advanced OA with features including the presence of stress fiber-positive myofibroblasts and deposition of cross-linked collagen type-I. Proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and is a major component of synovial fluid. PRG4 is a ligand of the CD44 receptor. Our objective was to examine the role of PRG4-CD44 interaction in regulating synovial tissue fibrosis in vitro and in vivo. Methods: OA synoviocytes were treated with TGF-β ± PRG4 for 24h and α-SMA content was determined using immunofluorescence. Rhodamine-labeled rhPRG4 was incubated with OA synoviocytes ± anti-CD44 or isotype control antibodies and cellular uptake of rhPRG4 was determined following a 30-min incubation and α-SMA expression following a 24-h incubation. HEK-TGF-β cells were treated with TGF-β ± rhPRG4 and Smad3 phosphorylation was determined using immunofluorescence and TGF-β/Smad pathway activation was determined colorimetrically. We probed for stress fibers and focal adhesions (FAs) in TGF-β-treated murine fibroblasts and fibroblast migration was quantified ± rhPRG4. Synovial expression of fibrotic markers: α-SMA, collagen type-I, and PLOD2 in Prg4 gene-trap (Prg4GT) and recombined Prg4GTR animals were studied at 2 and 9 months of age. Synovial expression of α-SMA and PLOD2 was determined in 2-month-old Prg4GT/GT&Cd44−/− and Prg4GTR/GTR&Cd44−/− animals. Results: PRG4 reduced α-SMA content in OA synoviocytes (p \u3c 0.001). rhPRG4 was internalized by OA synoviocytes via CD44 and CD44 neutralization attenuated rhPRG4’s antifibrotic effect (p \u3c 0.05). rhPRG4 reduced pSmad3 signal in HEKTGF- β cells (p \u3c 0.001) and TGF-β/Smad pathway activation (p \u3c 0.001). rhPRG4 reduced the number of stress fiberpositive myofibroblasts, FAs mean size, and cell migration in TGF-β-treated NIH3T3 fibroblasts (p \u3c 0.05). rhPRG4 inhibited fibroblast migration in a macrophage and fibroblast co-culture model without altering active or total TGF-β levels. Synovial tissues of 9-month-old Prg4GT/GT animals had higher α-SMA, collagen type-I, and PLOD2 (p \u3c 0.001) content and Prg4 re-expression reduced these markers (p \u3c 0.01). Prg4 re-expression also reduced α-SMA and PLOD2 staining in CD44-deficient mice. Conclusion: PRG4 is an endogenous antifibrotic modulator in the joint and its effect on myofibroblast formation is partially mediated by CD44, but CD44 is not required to demonstrate an antifibrotic effect in vivo

Potential Nephrotoxicity of Lisinopril and Valsartan on Patients with Congestive Heart Failure

Lisinopril (angiotensin converting enzyme inhibitor) and valsartan (angiotensin II receptor blocker) are the first-line treatment for patients with congestive heart failure (CHF). These two drugs potentially cause side effects on renal functions. However, limited information was available regarding the comparison of potential nephrotoxicity of these drugs in Indonesian CHF patients. This research was aimed to compare the potential nephrotoxicity between lisinopril and valsartan in outpatients with CHF at a hospital in Palu, Indonesia. This was an observational study conducted during April-May 2015. Potential nephrotoxicity were assessed by measuring serum creatinin (SCr) and blood urea nitrogen (BUN). Data were obtained from Cardiology Unit from a hospital in Palu, Indonesia. Statistical analysis was conducted using T-test and Mann-Whitney test. The increasing trend of SCr and BUN were observed in lisinopril-treated patients with the mean of increase were 21% and 59%, respectively. Relatively higher increase was observed in valsartan treatment group with 47% and 51% in SCr and BUN, respectively. The analysis showed that there were significant differences in SCr level between lisinopril and valsartan groups (p=0.001), but the opposite results observed in BUN parameter (p=0.697). Therefore, valsartan was potentially more nephrotoxic than lisinopril based on the increase of SCr parameter. Thus, lisinopril is recommended for CHF patients who are particularly at high risks of having renal impairment. Keywords: lisinopril, valsartan, nephrotoxicity, congestive heart failur

Sentinel node biopsy stands the test of time and the proof of time

International audienceObservational studies conducted in the 1970s, including that by Bernard Guerrier, cited by Bocca et al. [1], and subsequent studies published in the literature [2], have shown that neck dissection must be systematically performed in operable stage T1-T2N0 oral and oropharyngeal squamous cell carcinoma (OC) in order to diagnose and treat occult micrometastases [3]